These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 30239388)

  • 61. Arsenic derivatives as therapeutic agents for hematologic malignancies.
    Verstovsek S; Estrov Z
    Leuk Res; 2004 Sep; 28(9):901-3. PubMed ID: 15234564
    [No Abstract]   [Full Text] [Related]  

  • 62. [Hematologic malignancies/pediatric malignancies].
    Usui N
    Gan To Kagaku Ryoho; 2012 May; 39(5):731. PubMed ID: 22701898
    [No Abstract]   [Full Text] [Related]  

  • 63. [Limitations in application of imatinib in hematologic malignancies: are there new principal solutions?].
    Rukavitsyn OA; Pop VP
    Ter Arkh; 2008; 80(7):80-4. PubMed ID: 18763606
    [No Abstract]   [Full Text] [Related]  

  • 64. [Hematologic Malignancies/Pediatric Malignancies. Roles of Drugs Approved as New Agents and as Additional Indications for Relapse or Refractory Hematologic Malignancies].
    Usui N
    Gan To Kagaku Ryoho; 2016 May; 43(5):528-9. PubMed ID: 27344679
    [No Abstract]   [Full Text] [Related]  

  • 65. [Hematologic malignancies /pediatric malignancies-current status of molecular target therapy for hematologic cancer].
    Usui N
    Gan To Kagaku Ryoho; 2010 May; 37(5):805. PubMed ID: 20524247
    [No Abstract]   [Full Text] [Related]  

  • 66. How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses.
    Prasad V; Mailankody S
    Blood; 2015 Oct; 126(15):1860-1. PubMed ID: 26320099
    [No Abstract]   [Full Text] [Related]  

  • 67. ESH-SIOG International Conference on Haematological Malignancies in the Elderly.
    Balducci L
    Expert Rev Hematol; 2010 Dec; 3(6):675-7. PubMed ID: 21091143
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Acute tumor lysis syndrome: update on therapy].
    Jabbour E; Ribrag V
    Rev Med Interne; 2005 Jan; 26(1):27-32. PubMed ID: 15639323
    [TBL] [Abstract][Full Text] [Related]  

  • 69. New targets for hematologic malignancies.
    Bradner J
    Clin Adv Hematol Oncol; 2013 Jun; 11(6):375-6. PubMed ID: 24472807
    [No Abstract]   [Full Text] [Related]  

  • 70. The meaning of web-based communication for support: from the patients' perspective within a hematological healthcare setting.
    Högberg KM; Stockelberg D; Sandman L; Broström A; Nyström M
    Cancer Nurs; 2015; 38(2):145-54. PubMed ID: 24831039
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Unmet Needs for Psychosocial Care in Hematologic Malignancies and Hematopoietic Cell Transplant.
    Barata A; Wood WA; Choi SW; Jim HS
    Curr Hematol Malig Rep; 2016 Aug; 11(4):280-7. PubMed ID: 27113094
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Monoclonal antibodies in hematologic oncology].
    Kuliczkowski K; Podolak-Dawidziak M
    Pol Arch Med Wewn; 2002 May; 107(5):469-73. PubMed ID: 12189920
    [No Abstract]   [Full Text] [Related]  

  • 73. Hematologic malignancies: from clinical science to clinical practice - 2nd European Congress.
    Ferreri AJ
    IDrugs; 2006 Apr; 9(4):242-6. PubMed ID: 16596473
    [No Abstract]   [Full Text] [Related]  

  • 74. Quality of life and treatment value in the management of hematologic malignancies.
    Cella D; Webster KA
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):34-42. PubMed ID: 10561016
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Re: intravenous versus oral busulfan--perhaps not as different as suggested.
    Slattery JT
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):282-4. PubMed ID: 12720221
    [No Abstract]   [Full Text] [Related]  

  • 76. Management of hematological malignancies in patients affected by renal failure.
    Niscola P; Vischini G; Tendas A; Scaramucci L; Giovannini M; Bondanini F; Romani C; Brunetti GA; Cartoni C; Cupelli L; Ferrannini M; Perrotti A; Del Poeta G; Palumbo R; de Fabritiis P
    Expert Rev Anticancer Ther; 2011 Mar; 11(3):415-32. PubMed ID: 21417855
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Bendamustine: a new therapeutic option for hematologic malignancies.
    Cheson BD
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):631-3. PubMed ID: 18827785
    [No Abstract]   [Full Text] [Related]  

  • 78. [A role of new molecular-target drugs for hematologic malignancies].
    Usui N
    Gan To Kagaku Ryoho; 2015 May; 42(5):548-9. PubMed ID: 26054087
    [No Abstract]   [Full Text] [Related]  

  • 79. [Hematology: experiences with common national reports on new anti-cancer drugs].
    Kristensen JS; Bukh A
    Ugeskr Laeger; 2009 Mar; 171(13):1089. PubMed ID: 19321084
    [No Abstract]   [Full Text] [Related]  

  • 80. [Current developments in hematology and internal medicine oncology].
    Walshe R; Engert A; Diehl V
    Internist (Berl); 1998 Apr; 39(4):346-54. PubMed ID: 9599744
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.